MAPT and Alzheimer disease: Recent CSF S100B assessment in AD subjects revealed its strong correlation with CSF NSE, but not with other CSF biomarkers typical of AD like total tau protein, hyperphosphorylated tau protein (p-tau) and amyloid β1–42 (Aβ1–42; Christl et al., 2019).